GeneDx Holdings Corp. Class A Common Stock

GeneDx is trading at an RSI of just 30.8—deep in oversold territory—while shorts represent a hefty 27.36% of float, suggesting meaningful skepticism about the genomic testing specialist's fundamentals. With a $1.2B market cap and no profitable earnings (n/a P/E), the company remains pre-profitability, which explains both the depressed valuation and elevated short positioning. The extreme oversold condition combined with significant short interest creates potential squeeze dynamics, though the absence of positive earnings suggests the selling pressure may be fundamentally justified rather than panic-driven. Recovery would likely require demonstrable progress toward profitability in the competitive genomics market.